Typhoid, live attenuated, vaccine contains strains of Salmonella typhi, the etiological agent of typhoid fever, an acute, febrile enteric disease. The S. typhi Ty21a vaccine strain, by virtue of a reduction in enzymes essential for lipopolysaccharide biosynthesis, is restricted in its ability to produce complete lipopolysaccharide. However, a sufficient quantity of complete lipopolysaccharide is synthesized to evoke a protective immune response.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| J07AP01 | Typhoid, oral, live attenuated | J Antiinfectives for systemic use → J07 Vaccines → J07A Bacterial vaccines → J07AP Typhoid vaccines |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| VIVOTIF Typhoid vaccine capsule | FDA, National Drug Code (US) | MPI, US: SPL/Old |
Typhoid, live attenuated is an active ingredient of these brands:
United States (US)Austria (AT)Canada (CA)Finland (FI)Hong Kong (HK)New Zealand (NZ)Poland (PL)Singapore (SG)South Africa (ZA)Spain (ES)United Kingdom (UK)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
